August 5, 2008
Xanodyne Achieves Positive Efficacy Results in Pivotal Phase 3 Studies of Proprietary Modified Release Oral Tranexamic Acid Product Candidate for Heavy Menstrual Bleeding
July 22, 2008
Xanodyne Receives Approvable Letter From the U.S. Food and Drug Administration for ZIPSOR™ (diclofenac potassium) Capsules
February 6, 2008
Xanodyne Announces Two Senior Appointments
[ Corporate Governance ]
Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. We market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.
We are developing: Zipsor™ for the treatment of mild to moderate acute pain for which we have received an Approvable Letter from the U.S. Food & Drug Administration (FDA); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line Phase 3 clinical data and NDA filing is being completed; and XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S.
Oramorph is a sustained relief morphine oral tablet indicated for pain in patients who require opioid analgesia for more than a few days... [MORE]
Duet DHA EC offers 15 essential vitamins and minerals plus the most omega-3 LCFAs* in the only enteric-coated capsule available in a prescription prenatal vitamin.... [MORE]
